Role of Mast Cells in Shaping the Tumor Microenvironment.
Cancer
Extracellular matrix
Immunosuppression
Mast cell
Tumor
Journal
Clinical reviews in allergy & immunology
ISSN: 1559-0267
Titre abrégé: Clin Rev Allergy Immunol
Pays: United States
ID NLM: 9504368
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
pubmed:
1
7
2019
medline:
29
12
2020
entrez:
1
7
2019
Statut:
ppublish
Résumé
Early mast cell (MC) infiltration has been reported in a wide range of human and animal tumors particularly malignant melanoma and breast and colorectal cancer. The consequences of their presence in the tumor microenvironment (TME) or at their margins still remain unclear as it is associated with a good or poor prognosis based on the type and anatomical site of the tumor. Within the tumor, MC interactions occur with infiltrated immune cells, tumor cells, and extracellular matrix (ECM) through direct cell-to-cell interactions or release of a broad range of mediators capable of remodeling the TME. MCs actively contribute to angiogenesis and induce neovascularization by releasing the classical proangiogenic factors including VEGF, FGF-2, PDGF, and IL-6, and nonclassical proangiogenic factors mainly proteases including tryptase and chymase. MCs support tumor invasiveness by releasing a broad range of matrix metalloproteinases (MMPs). MC presence within the tumor gained additional significance when it was assumed that controlling its activation by tyrosine kinase inhibitors (imatinib and masitinib) and tryptase inhibitors (gabexate and nafamostat mesylate) or controlling their interactions with other cell types may have therapeutic benefit.
Identifiants
pubmed: 31256327
doi: 10.1007/s12016-019-08753-w
pii: 10.1007/s12016-019-08753-w
pmc: PMC7244463
doi:
Substances chimiques
Intercellular Signaling Peptides and Proteins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
313-325Références
Prostate. 2017 Mar;77(4):412-424
pubmed: 27868214
Cell Signal. 2017 Sep;37:81-92
pubmed: 28600192
Tumour Biol. 2017 Apr;39(4):1010428317699133
pubmed: 28381169
Sci Rep. 2016 Dec 06;6:38352
pubmed: 27922077
PLoS One. 2010 Jan 27;5(1):e8922
pubmed: 20111717
Nat Commun. 2017 Aug 16;8(1):269
pubmed: 28814715
Cancer Microenviron. 2015 Dec;8(3):167-76
pubmed: 25194694
Blood. 2008 Aug 15;112(4):1269-79
pubmed: 18524989
Eur J Pharmacol. 2016 May 5;778:152-7
pubmed: 25917325
Bull Exp Biol Med. 2017 Oct;163(6):801-804
pubmed: 29063337
Cancer Res. 2011 Sep 15;71(18):5987-97
pubmed: 21896641
Int J Oncol. 2009 Jul;35(1):115-20
pubmed: 19513558
Int J Endocrinol. 2015;2015:705169
pubmed: 26379707
Indian J Pathol Microbiol. 2009 Jan-Mar;52(1):20-4
pubmed: 19136773
Cell Immunol. 1991 Jul;135(2):541-8
pubmed: 1709829
PLoS One. 2011;6(9):e25222
pubmed: 21949886
Appl Immunohistochem Mol Morphol. 2017 Nov/Dec;25(10):e83-e88
pubmed: 29116959
J Cancer Res Ther. 2018 Apr-Jun;14(3):495-502
pubmed: 29893305
Ann Surg Oncol. 2017 May;24(5):1435-1442
pubmed: 27896514
Acta Dermatovenerol Croat. 2017 Jul;25(2):112-119
pubmed: 28871925
Front Oncol. 2016 Oct 17;6:218
pubmed: 27800303
Clin Rev Allergy Immunol. 2018 Jun;54(3):397-411
pubmed: 28725969
Oncogene. 2015 Oct 1;34(40):5175-86
pubmed: 25619830
Nat Rev Cancer. 2017 Aug;17(8):457-474
pubmed: 28706266
Cancer Lett. 2015 Nov 1;368(1):7-13
pubmed: 26276713
Oncol Lett. 2017 Sep;14(3):3193-3198
pubmed: 28927065
Oncogene. 2017 May 18;36(20):2879-2888
pubmed: 28114284
Mol Cancer Ther. 2017 Feb;16(2):365-375
pubmed: 27980106
Clin Rev Allergy Immunol. 2019 Apr;56(2):234-247
pubmed: 30506113
J Clin Invest. 1997 Jun 1;99(11):2691-700
pubmed: 9169499
PLoS One. 2016 Nov 28;11(11):e0163661
pubmed: 27893746
Anticancer Res. 2017 Mar;37(3):1013-1021
pubmed: 28314259
PLoS One. 2018 Jan 10;13(1):e0191012
pubmed: 29320562
Oncotarget. 2017 Jul 31;8(41):70463-70471
pubmed: 29050294
World J Gastroenterol. 2014 Jul 21;20(27):8910-20
pubmed: 25083063
F1000Res. 2017 Oct 26;6:1889
pubmed: 29225779
J Immunol. 2010 Dec 1;185(11):7067-76
pubmed: 21041732
Exp Cell Res. 2015 Mar 15;332(2):157-62
pubmed: 25478999
Leukemia. 2012 Oct;26(10):2269-76
pubmed: 22430634
Mol Oncol. 2014 Feb;8(1):50-8
pubmed: 24091309
Clin Exp Med. 2017 Feb;17(1):71-77
pubmed: 26886279
Exp Cell Res. 2017 Oct 1;359(1):179-184
pubmed: 28756894
Anal Cell Pathol (Amst). 2016;2016:6891971
pubmed: 27882290
Biomed Res Int. 2014;2014:154702
pubmed: 25295247
Clin Exp Allergy. 2004 Nov;34(11):1660-4
pubmed: 15544587
Clin Rev Allergy Immunol. 2017 Jun;52(3):436-445
pubmed: 28025778
Eur Urol. 2006 Sep;50(3):530-4
pubmed: 16426730
J Immunol. 2006 Nov 15;177(10):7275-86
pubmed: 17082646
Pathol Res Pract. 2017 Jun;213(6):612-618
pubmed: 28552539
J Allergy Clin Immunol. 2007 Oct;120(4):827-34
pubmed: 17681365
Crit Rev Oncol Hematol. 2017 Jul;115:23-26
pubmed: 28602166
Int J Mol Sci. 2016 Nov 15;17(11):
pubmed: 27854307
Front Immunol. 2018 Sep 20;9:2138
pubmed: 30294327
Front Med (Lausanne). 2017 Jul 24;4:103
pubmed: 28791287
Clin Exp Med. 2017 Nov;17(4):531-539
pubmed: 28105541
Cancer Lett. 2017 Jul 1;397:23-32
pubmed: 28342985
Allergy. 2017 Jun;72(6):866-887
pubmed: 28032353
Cell Rep. 2018 Jan 2;22(1):27-35
pubmed: 29298428
Int J Cancer. 2018 Feb 15;142(4):813-821
pubmed: 29023696
J Cell Mol Med. 2013 Aug;17(8):1025-37
pubmed: 23991686
Front Immunol. 2017 Apr 12;8:424
pubmed: 28446910
Cancer Immunol Res. 2018 Mar;6(3):332-347
pubmed: 29382671
Semin Cancer Biol. 2015 Oct;34:36-45
pubmed: 26232774
Arch Immunol Ther Exp (Warsz). 2016 Dec;64(6):515-522
pubmed: 27289241
Inflamm Res. 2017 Oct;66(10):871-879
pubmed: 28616734
Pol J Pathol. 2014 Jun;65(2):147-53
pubmed: 25119176
Life Sci. 2017 May 1;176:35-41
pubmed: 28336398
Br J Haematol. 2002 Oct;119(1):122-4
pubmed: 12358914
Transfus Med Hemother. 2016 Mar;43(2):109-13
pubmed: 27330532
J Allergy Clin Immunol. 2009 May;123(5):1142-9, 1149.e1-5
pubmed: 19275959
Am Soc Clin Oncol Educ Book. 2013;:
pubmed: 23714465
Oncogene. 2010 Nov 25;29(47):6203-15
pubmed: 20729915
Biochim Biophys Acta. 2012 Jan;1822(1):2-8
pubmed: 21130163
Mediators Inflamm. 2015;2015:246126
pubmed: 25944979
Oncotarget. 2015 Sep 15;6(27):23647-61
pubmed: 26164207
Hum Immunol. 2012 Jan;73(1):17-25
pubmed: 22057035
Oncotarget. 2014 May 30;5(10):3159-67
pubmed: 24931643
Int Rev Cell Mol Biol. 2009;275:89-131
pubmed: 19491054
Oncoimmunology. 2018 Aug 24;7(11):e1504729
pubmed: 30377568
J Hematol Oncol. 2017 Feb 28;10(1):58
pubmed: 28241846
J Am Soc Nephrol. 2012 Dec;23(12):1913-4
pubmed: 23138481
Ann N Y Acad Sci. 2008 Nov;1144:74-82
pubmed: 19076366
Cancer Med. 2016 Jun;5(6):1292-7
pubmed: 26992445
Int J Mol Sci. 2016 May 27;17(6):
pubmed: 27240355
Cell Death Dis. 2018 Jan 25;9(2):115
pubmed: 29371595
Histopathology. 2011 Jun;58(7):1096-106
pubmed: 21707711